E Fund CSI Biotechnology Theme ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

159849

512010

159992

159316

513700

159837

516500

512290

516930

159570

Relay Therapeutics has launched a public offering of $175 million in common stock, with all shares sold by the company. Underwriters have a 30-day option to purchase an additional 15% of shares. Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities are the joint bookrunners. The offering is subject to market conditions.

PUBT

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Direxion S&P Biotech Bull 3X

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares Biotechnology ETF

VG Health

iShares Global Healthcare

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Guotai CSI Bio-medicine ETF

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ALPS Medical Breakthrough

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

VanEck Biotech ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Relay Therapeutics

Jefferies Financial

Goldman Sachs

GS Hldg R

Relay Therapeutics launches $175 million common stock offering

159859

159615

588250

159102

Ipsen announced findings from the Phase IV DIRECTION trial comparing Dysport and Botox for upper limb spasticity. The results, presented at the ISPRM congress in Vancouver on May 19, 2026, showed Dysport had a similar safety profile to Botox and offered longer-lasting symptom relief.

Unusual Whales

Tianhong CNI BIOMEDICINE ETF

Proshares UltraShort Nasdaq Biotech

China Southern Hang Seng Biotech ETF(QDII)

Invesco Nasdaq Biotechnology ETF

BlackRock, Inc.

Penghua SSE STAR Biology and Medicine ETF

SPDR S&P Biotech

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

The Purina Institute is advancing microbiome science in veterinary medicine, focusing on the gut-brain axis and antimicrobial stewardship. Their Microbiome Forum highlighted how gut health influences neurological conditions in pets and emphasized the need for responsible antimicrobial use to protect long-term health. By translating complex research into practical insights, the Institute aims to empower veterinarians to enhance pet health through informed dietary and treatment strategies.

prnewswire

08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine

000688

科创综指

588170

The STAR Market has risen 78.98% in the past year, gathering 609 hard technology companies, with a total market value exceeding 13 trillion yuan. In 2025, revenue is expected to be nearly 1.6 trillion yuan, with a net profit exceeding 58.6 billion yuan. In the first quarter of 2026, revenue is projected to be 385.3 billion yuan, with a net profit attributable to the parent company of 23.4 billion yuan, a year-on-year increase of nearly 200%. The "1+6" system of the STAR Market promotes the development of technology companies, focusing on fields such as artificial intelligence and commercial aerospace, showcasing the innovative vitality and development potential of hard technology enterprises

同壁财经

STAR 50

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

E Fund China Science and Technology Innovation Board 50 Component ETF

Huatai-PB SSE Science and Technology Innovation Board Composite ETF

ChinaAMC SSE Science and Technology Innovation Board 50 ETF

ChinaAMC SSE Science and Technology Innovation Board Composite ETF

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

Guotai CES Semiconductor Chip Industry ETF

Huatai-PB SSE Science and Technology Innovation Board 50 ETF

Guotai CSI Semiconductor Material Equipment Theme ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

TF SECURITIES

CCB Principal SSE Science and Technology Innovation Board Composite ETF

The STAR Market's performance has exploded, with net profit increasing by nearly 200% in the first quarter, gathering integrated circuits, biomedicine, and high-end equipment. The STAR Composite Index has risen by 78.98% in nearly one year

Nanjing's Leads Biolabs Co., Ltd. revealed today that their exclusive PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has been approved by the Center for Drug Evaluation. This announcement was made under the Stock Code.

LEADS BIOLABS-B

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. announced that its PD-L1/4-1BB bispecific antibody, Opamtistomig, has received approval for a pivotal Phase III trial for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). This marks a shift from late-line to first-line treatment, expanding its patient population. The study, led by Professor Lin Shen, aims to validate Opamtistomig's potential to improve patient survival. The company plans to submit a Biologics License Application in Q3 2026 and is advancing multiple trials across various solid tumor indications.

21:35 ETLeads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

01801

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

REMEGEN

RemeGen

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

E Fund CSI Biotechnology Theme ETF(159837.SZ)